-
Innovation Ranking
NewInnovation Ranking – MorphoSys AG
MorphoSys AG (Morphosys) is commercial-stage biopharmaceutical company that develop monoclonal antibodies for therapeutic and research applications, with focused on the treatment of cancer and autoimmune diseases. The company's product pipeline includes tafasitamab, pelabresib, cpi-0209, gantenerumab, otilimab, ianalumab, abelacimab, felzartamab, setrusumab, NOV-8, NOV-14 and MOR210. Its Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody directed against CD19 in clinical development for the treatment of B cell malignancies. The company provides clinical trials for cancer and inflammatory disorders. Morphosys also...
-
Product Insights
NewNet Present Value Model: MorphoSys AG’s Pelabresib
Empower your strategies with our Net Present Value Model: MorphoSys AG's Pelabresib report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: MorphoSys AG’s Pelabresib
Empower your strategies with our Net Present Value Model: MorphoSys AG's Pelabresib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of MorphoSys AG Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of MorphoSys AG Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Guselkumab in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Guselkumab in Hidradenitis Suppurativa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Guselkumab in Hidradenitis Suppurativa Drug Details: Guselkumab (CNTO-1959, Tremfya, Tremfya One-Press) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Guselkumab in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Guselkumab in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Guselkumab in Lupus Nephritis Drug Details: Guselkumab (CNTO-1959, Tremfya, Tremfya One-Press) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Guselkumab in Polyarticular Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Guselkumab in Polyarticular Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Guselkumab in Polyarticular Arthritis Drug Details: Guselkumab (CNTO-1959, Tremfya, Tremfya One-Press) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Guselkumab in Psoriasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Guselkumab in Psoriasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Guselkumab in Psoriasis Drug Details: Guselkumab (CNTO-1959, Tremfya, Tremfya One-Press) is a human...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tulmimetostat in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tulmimetostat in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tulmimetostat in Fallopian Tube Cancer Drug Details: Tulmimetostat is under...